Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.70 |
| ▸ | RAB9A | P51151 | 4/20 | 0.70 |
| ▸ | NPC1 | O15118 | 3/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.70 |
| ▸ | ATM | Q13315 | 1/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 8/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31524108 | 0.91 | MAPT (0.79) | MAPTRAB9ANPC1LMNAMAPK1 | |
| SCHEMBL374408 | 0.89 | RAB9A (0.65) | MAPTRAB9ANPC1LMNAMAPK1 | |
| SCHEMBL29878324 | 0.87 | MAPT (0.63) | MAPTRAB9ANPC1LMNAMAPK1 | |
| SCHEMBL1408801 | 0.87 | MAPT (0.63) | MAPTRAB9ANPC1LMNAMAPK1 | |
| SCHEMBL1456071 | 0.86 | MAPT (0.58) | MAPTRAB9ANPC1LMNAMAPK1 | |
| SCHEMBL31151736 | 0.85 | MAPT (0.62) | MAPTRAB9ANPC1LMNAMAPK1 | |
| SCHEMBL1408857 | 0.83 | MAPT (0.64) | MAPTRAB9ANPC1LMNAMAPK1 | |
| SCHEMBL4829609 | 0.83 | MAPT (0.67) | MAPTRAB9ANPC1LMNAMAPK1 | |
| SCHEMBL17103383 | 0.83 | CSF1R (0.64) | MAPTRAB9ANPC1LMNAMAPK1 | |
| SCHEMBL29878811 | 0.82 | MAPT (0.60) | MAPTRAB9ANPC1LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2295424-B1 | Processes for the preparation of novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase | NATCO PHARMA LTD (IN) | 2015-10-14 | — | — | EP | claimed |
| US-8067422-B2 | Crystal form of phenylamino pyrimidine derivatives | NATCO PHARMA LIMITED (IN) | 2011-11-29 | — | — | US | claimed |
| EP-2295424-A1 | Processes for the preparation of novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase | Natco Pharma Limited (IN) | 2011-03-16 | — | — | EP | claimed |
| US-20090227611-A1 | CRYSTAL FORM OF PHENYLAMINO PYRIMIDINE DERIVATIVES | NATCO PHARMA LIMITED (IN) | 2009-09-10 | — | — | US | claimed |
| US-20080306100-A1 | PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | NATCO PHARMA LIMITED (IN) | 2008-12-11 | — | — | US | claimed |
| EP-2295424-B1 | Processes for the preparation of novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase | NATCO PHARMA LTD (IN) | 2015-10-14 | — | — | EP | disclosed |
| EP-2265599-B1 | CRYSTAL FORM OF PHENYLAMINOPYRIMIDINE DERIVATIVE | NATCO PHARMA LTD (IN) | 2013-11-20 | — | — | EP | disclosed |
| CN-102015681-B | Crystal form of phenylamino pyrimidine derivatives | NATCO PHARMA LTD | 2013-08-28 | — | — | CN | disclosed |
| US-8183253-B2 | Condensing (3-trifluoromethylsulfonyl) benzoyl chloride and 4-methyl-2-nitro-aniline; reducing nitro group with stannous chloride; condensing amino group with cyanamide; cyclocondensing guanidine group with 3-dimethylamino-1-pyridin-3-yl-propenone; antiproliferative agents; chronic myeloid leukemia | NATCO PHARMA LIMITED (IN) | 2012-05-22 | — | — | US | disclosed |
| US-8067422-B2 | Crystal form of phenylamino pyrimidine derivatives | NATCO PHARMA LIMITED (IN) | 2011-11-29 | — | — | US | disclosed |
| EP-2265599-A2 | CRYSTAL FORM OF PHENYLAMINO PYRIMIDINE DERIVATIVE | Natco Pharma Limited (IN) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009109867-A2 | CRYSTAL FORM OF PHENYLAMINO PYRIMIDINE DERIVATIVES | NATCO PHARMA LIMITED (IN) | 2009-09-11 | — | — | WO | disclosed |
| US-20090227611-A1 | CRYSTAL FORM OF PHENYLAMINO PYRIMIDINE DERIVATIVES | NATCO PHARMA LIMITED (IN) | 2009-09-10 | — | — | US | disclosed |
| US-20080306100-A1 | PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | NATCO PHARMA LIMITED (IN) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306100-A1 | PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | ABL1, ABL2, BCR | MAPT 3099/4885RAB9A 2568/4885NPC1 3258/4885 |
| US-20090227611-A1 | CRYSTAL FORM OF PHENYLAMINO PYRIMIDINE DERIVATIVES | WEE1, TP53, CDKN1A | MAPT 1254/4885RAB9A 890/4885NPC1 2392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.